BRPI1012077B8 - composição nutricional compreendendo uma combinação de uma fonte de leucina e uma fonte de ácido graxo poli-insaturado o-3, carboidratos digeríveis e fibra dietética solúvel - Google Patents

composição nutricional compreendendo uma combinação de uma fonte de leucina e uma fonte de ácido graxo poli-insaturado o-3, carboidratos digeríveis e fibra dietética solúvel

Info

Publication number
BRPI1012077B8
BRPI1012077B8 BRPI1012077A BRPI1012077A BRPI1012077B8 BR PI1012077 B8 BRPI1012077 B8 BR PI1012077B8 BR PI1012077 A BRPI1012077 A BR PI1012077A BR PI1012077 A BRPI1012077 A BR PI1012077A BR PI1012077 B8 BRPI1012077 B8 BR PI1012077B8
Authority
BR
Brazil
Prior art keywords
source
combination
fatty acid
leucine
nutritional composition
Prior art date
Application number
BRPI1012077A
Other languages
English (en)
Inventor
Van Norren Klaske
Faber Joyce
Lambertus Bertholdus Van Helvoort Adrianus
Johan Joseph Hageman Robert
Original Assignee
Nutricia Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41397536&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1012077(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nutricia Nv filed Critical Nutricia Nv
Publication of BRPI1012077A2 publication Critical patent/BRPI1012077A2/pt
Publication of BRPI1012077B1 publication Critical patent/BRPI1012077B1/pt
Publication of BRPI1012077B8 publication Critical patent/BRPI1012077B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMBINAÇÃO DE UMA FONTE DE LEUCINA E UMA FONTE DE ÁCIDO GRAXO, E, COMPOSIÇÃO NUTRICIONAL, UMA COMPOSIÇÃO FARMACÊUTICA OU UMA COMPOSIÇÃO NUTRACÊUTICA A invenção se relaciona a uma combinação de uma fonte de leucina e pelo menos uma fonte de ácido graxo insaturado para tratamento terapêutico ou profilático de hipercaucemia. A invenção ainda se relaciona a uma combinação de uma fonte de leucina e pelo menos uma fonte de ácido graxo insaturado para reduzir ou evitar a redução da densidade mineral óssea ou para regulação in vivo da homeostase de cálcio no plasma do sangue.
BRPI1012077A 2009-05-27 2010-05-27 composição nutricional compreendendo uma combinação de uma fonte de leucina e uma fonte de ácido graxo poli-insaturado o-3, carboidratos digeríveis e fibra dietética solúvel BRPI1012077B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NLPCT/NL2009/050297 2009-05-27
PCT/NL2009/050297 WO2010137944A1 (en) 2009-05-27 2009-05-27 Treatment of hypercalcaemia
PCT/NL2010/050319 WO2010137979A2 (en) 2009-05-27 2010-05-27 Hypercalcaemia

Publications (3)

Publication Number Publication Date
BRPI1012077A2 BRPI1012077A2 (pt) 2018-03-20
BRPI1012077B1 BRPI1012077B1 (pt) 2021-05-18
BRPI1012077B8 true BRPI1012077B8 (pt) 2022-09-20

Family

ID=41397536

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1012077A BRPI1012077B8 (pt) 2009-05-27 2010-05-27 composição nutricional compreendendo uma combinação de uma fonte de leucina e uma fonte de ácido graxo poli-insaturado o-3, carboidratos digeríveis e fibra dietética solúvel

Country Status (12)

Country Link
US (2) US20120122785A1 (pt)
EP (2) EP2435039B2 (pt)
CN (2) CN102458390B (pt)
BR (1) BRPI1012077B8 (pt)
DK (1) DK2435039T4 (pt)
ES (1) ES2555860T5 (pt)
HU (1) HUE028295T2 (pt)
MX (1) MX2011012573A (pt)
PL (1) PL2435039T5 (pt)
PT (1) PT2435039E (pt)
RU (1) RU2555359C2 (pt)
WO (2) WO2010137944A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
WO2012141575A1 (en) 2011-04-14 2012-10-18 N.V.Nutricia Combination of epa, dpa and/or dha with a chemotherapeutic agent
JP2014511890A (ja) * 2011-04-18 2014-05-19 ネステク ソシエテ アノニム α−ＨＩＣＡ及びα−ケトグルタル酸を含有する栄養組成物
WO2015002527A1 (en) 2013-07-05 2015-01-08 N.V. Nutricia Amino acid composition for use in the treatment of a pdd
US9616292B2 (en) * 2015-01-09 2017-04-11 Nolan Orfield Exercise tracker
US11197917B2 (en) 2017-12-01 2021-12-14 ByHeart, Inc. Formulations for nutritional support in subjects in need thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05178758A (ja) * 1991-03-22 1993-07-20 Suntory Ltd トリペプチドを有効成分とする骨疾患の予防および治療剤
EP0504938A3 (en) * 1991-03-22 1993-04-14 Suntory Limited Prophylactic and therapeutic agent for bone diseases comprising di- or tripeptide derivative as active ingredient
JPH05140063A (ja) * 1991-11-19 1993-06-08 Suntory Ltd ジペプチド誘導体及びそれを有効成分とする骨疾患の予防及び治療剤
US6077828A (en) * 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
US20070037777A1 (en) * 2005-08-12 2007-02-15 Immunopath Profile, Inc. Lipid-containing compositions and methods of using them
GB0003310D0 (en) 2000-02-15 2000-04-05 Univ Sheffield Bone formation
NL1019368C2 (nl) 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
US20040087490A1 (en) * 2002-09-20 2004-05-06 Troup John P. Nutritional compositions
US20040171692A1 (en) * 2003-02-28 2004-09-02 Scutt Andrew Modulation of bone formation
MXPA05009933A (es) 2003-03-18 2005-11-04 Novartis Ag Composiciones que comprenden acidos grasos y aminoacidos.
ATE433674T1 (de) * 2003-06-23 2009-07-15 Nestec Sa Säuglingsnährpräparat oder folgemilch
JP4702678B2 (ja) * 2004-06-07 2011-06-15 環境創研株式会社 競走馬用飼料添加材
CA2573338C (en) 2004-07-28 2013-07-02 Abbott Laboratories A nutritional composition comprising dried fruit solids and an oligosaccharide and its use for treating osteoporosis
EP1800675B1 (en) 2005-12-23 2011-05-18 N.V. Nutricia Composition comprising polyunsaturated fatty acids, proteins, manganese and/or molybden and nucleosides/nucleotides for treating dementia
GB0624879D0 (en) * 2006-12-14 2007-01-24 Shs Int Ltd Treatment of pervasive development disorders
US20080171791A1 (en) * 2007-01-11 2008-07-17 Mdr Fitness Corp. Compositions and Method for Losing Weight
US20080200425A1 (en) * 2007-02-16 2008-08-21 Kurtz Seymour J Methods and compositions for regulating bone mineral density
WO2008147228A1 (en) * 2007-05-31 2008-12-04 Fonterra Corporate Research And Development Limited Treatment or prevention of bone conditions
US7893067B2 (en) * 2007-06-27 2011-02-22 Medivir Ab Cysteine protease inhibitors
EP2025248A1 (en) * 2007-07-31 2009-02-18 Fresenius Kabi Deutschland GmbH Cachexia prevention supplement
WO2010002242A1 (en) * 2008-07-02 2010-01-07 N.V. Nutricia Nutritional composition for improving muscle function and daily activity
CN101314031A (zh) * 2008-07-14 2008-12-03 王冰 一种改善骨营养的制剂

Also Published As

Publication number Publication date
RU2555359C2 (ru) 2015-07-10
HUE028295T2 (en) 2016-12-28
WO2010137979A8 (en) 2011-11-17
BRPI1012077A2 (pt) 2018-03-20
EP2435039B2 (en) 2019-02-27
MX2011012573A (es) 2011-12-14
CN102458390B (zh) 2014-10-29
CN104257646A (zh) 2015-01-07
DK2435039T3 (en) 2015-12-21
EP2987485A1 (en) 2016-02-24
US20120122785A1 (en) 2012-05-17
BRPI1012077B1 (pt) 2021-05-18
WO2010137979A3 (en) 2011-04-14
WO2010137944A1 (en) 2010-12-02
CN102458390A (zh) 2012-05-16
WO2010137979A2 (en) 2010-12-02
ES2555860T5 (es) 2019-07-12
US9867796B2 (en) 2018-01-16
US20150018277A1 (en) 2015-01-15
EP2435039B1 (en) 2015-09-09
PT2435039E (pt) 2016-01-08
PL2435039T3 (pl) 2016-02-29
PL2435039T5 (pl) 2019-09-30
EP2987485B1 (en) 2020-02-26
ES2555860T3 (es) 2016-01-11
EP2435039A2 (en) 2012-04-04
DK2435039T4 (da) 2019-05-06
RU2011152873A (ru) 2013-07-10

Similar Documents

Publication Publication Date Title
BRPI1012077B8 (pt) composição nutricional compreendendo uma combinação de uma fonte de leucina e uma fonte de ácido graxo poli-insaturado o-3, carboidratos digeríveis e fibra dietética solúvel
BRPI0814726A2 (pt) fortificação de produtos nutricionais com extratos de oliveiras contendo hidroxitirosol e produtos nutricionais fortificados com hidroxitirosol
EP3318262A3 (en) Composition for preventing or treating bone disease, obesity and lipid-related metabolic disease
BR112014033102A2 (pt) produto para uso no tratamento profilático ou terapêutico de uma emoção negativa ou comportamento introvertido
MX2010002404A (es) Composiciones de grasa solida que contiene un acido graso poliinsaturado y usos y produccion de las mismas.
PH12014500558A1 (en) Composition for use in the promotion of healthy bone growth and/or in the prevention and/or treatment of bone disease
BR112012010586A2 (pt) suplementos nutricionais para alívio de segura no olho.
MA33075B1 (fr) Composition destinee a la regulation du metabolism des lipides
PH12013501892A1 (en) Nutritional compositions including branched chain fatty acids for wound healing
NZ618734A (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
NO20085374L (no) Anvendelse av fytat som middel for a inhibere opplosning av krystaller av kalsiumsalter for forhindring av osteoporose
PE20121406A1 (es) Cepas de lactobacillus plantarum como agentes hipocolesterolemicos
MX2013010076A (es) Composiciones y metodos que comprenden c16:1n7 palmitoleato.
WO2011036316A3 (es) Uso de extractos vegetales como prebióticos, composiciones y alimentos que los contienen
PH12014500790A1 (en) Infant formula with high sn-2 palmitate and oligofructose
TR201910903T4 (tr) Osteoporoz hastalıkları profilaksisi için biyolojik olarak aktif gıda katkısı.
PH12014502811B1 (en) Dietary management of celiac disease and food allergy
WO2011143048A3 (en) Methods for the diagnosis, control and prophylaxis of inflammation and mitigation of inflammatory conditions in canines
WO2011019875A3 (en) Antioxidant dietary supplement compositions
ECSP13012798A (es) Método para inhibir patógenos usando una composición nutricional
WO2007109071A3 (en) Hydroxylated polymethoxyflavone compositions
BR112013026487A2 (pt) composição, e, método para intensificar o efeito de um agente quimioterapêutico
TR201004464A2 (tr) Kemik erimesi için formülasyon.
WO2010146078A3 (en) Novel uses of hydroxyproline compositions
WO2010117346A3 (en) Stable pharmaceutical compositions with high bioavailability

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/05/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/05/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B16B Notification of grant cancelled [chapter 16.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 16.3 NA RPI NO 2629 DE 25/05/2021 POR TER SIDO INDEVIDA.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: RETIFICACAO REF. RPI 2628 DE 18/05/2021. PRAZO DE VALIDADE: 10 ANOS CONTADOS A PARTIR DE 18/05/2021, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME A ADI 5.529/DF, COM APOSTILAMENTO DO PRAZO DE VALIDADE DA PROTECAO DA MATERIA RELATIVA A PRODUTOS E PROCESSOS FARMACEUTICOS E EQUIPAMENTOS E/OU MATERIAIS DE USO EM SAUDE, PARA APLICACAO EM HUMANOS.